China Human Vaccine Industry Report, 2010-2011
  • May/2011
  • Hard Copy
  • USD $2,300
  • Pages:92
  • Single User License
    (PDF Unprintable)       
  • USD $2,200
  • Code: HM001
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,500
With the improvement of economy and people’s disease prevention awareness, China’s human vaccine market has expanded in recent years, growing at a CAGR of 24.0% in 2007-2010. In particular, the market scale in 2010 hit RMB10.3 billion, up 14.4% year-on-year.

Human Vaccine Market Scale, 2007-2010 (RMB bn)
Source: ResearchInChina

Under the influence of China’s actual conditions and the vaccine industry characteristics, state-owned human vaccine enterprises take a lion’s share in the market, especially in the EPI (Expanded Program on Immunization) vaccines market. In terms of lot release quantity, state-owned enterprises occupied 68.1% of the extra EPI vaccines market in 2010. For example, meningococcal vaccines and hepatitis A vaccine are mainly offered by stated-owned enterprises including 6 research institutions under China National Biotec Group and Kunming Branch of Chinese Academy of Medical Science.

Granted, with the industry development, China’s vaccine market is lowering its entry barrier and becoming more open. And private enterprises have become a new force in the extra EPI vaccines market, with market share soaring. Likewise, foreign enterprises are also major players in the extra EPI vaccines market by virtue of their technology and product advantages. In 2010, the market share of private enterprises and foreign enterprises in the extra EPI vaccines market marked 39.8% and 15.5% by lot release quantity respectively.

Taking HIB vaccine market for example, the market share of private enterprises and foreign ones in 2010 combined to 59.9% by lot release quantity. But in the pneumonia vaccines market, foreign enterprises including Sanofi Pasteur and Wyeth took up 49.6% by lot release quantity in 2010.

Although domestic enterprises have taken the leading position in the EPI vaccines market, they are going into overdrive to develop the highly profitable extra EPI vaccines market and have made some achievements. A case in point is Sinovac Biotech Co., Ltd., which is conducting clinical trial for its 13-valence pneumonia vaccine; on December 24th, 2010, the 71-type inactivated vaccine for hand-foot-month disease and enterovirus developed by China National Biotec Group was approved by the State Food and Drug Administration for clinical study.

Moreover, domestic vaccine enterprises have scored significant achievement in the R&D of therapeutic vaccines. For example, Chongqing Brewery has made smooth progress in the clinical trial of synthetic peptide hepatitis b vaccine. As of Feb. 2011, 101 subjects had finished 76-week-long phase II b clinical trial of the vaccine. Changchun High & New Technology Industries Group, the only listed company of China engaged in the R&D of AIDS vaccine, started the phase I clinical trial for its therapeutic AIDS vaccine in March 2011.
1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry & Market 
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.2.3 Biopharmaceutical Market in China
2.3. Status Quo 
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Dynamics

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price 
3.2 Meningococcal Vaccines
3.2.1 Supply & Demand
3.2.2 Competition Pattern 
3.2.3 Market Price 
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price 
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price 
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern 
3.5.3 Market Price 
3.5.4 Market Forecast
3.6 Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern 
3.6.3 Market Price 
3.6.4 Dynamics
3.6.5 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price 
3.8 Pneumococcal Vaccines
3.8.1 Supply & Demand 
3.8.2 Competition Pattern 
3.8.3 Market Price 

4. China’s Import and Export of Vaccines in 2010-2011
4.1 Human Vaccines
4.1.1 Import
4.1.2 Export

5. Major Vaccine Manufacturers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd
5.1.2 Shanghai Institute of Biological Products
5.2 Hualan Biological Engineering Inc.
5.2.1 Operation
5.2.2 Operation of Vaccine Business
5.2.3 Prospect of Vaccine Business
5.3 Liaoning Chengda Biotechnology Co., Ltd
5.3.1 Operation
5.3.2 Operation of Vaccine Business
5.3.3 Prospect of Vaccine Business
5.4 Chongqing Zhifei Biological Products Co., Ltd
5.4.1 Profile
5.4.2 Operation
5.4.3 Development Plan
5.5 Walvax Biotechnology Co., Ltd
5.5.1 Profile
5.5.2 Operation
5.5.3 Vaccine Projects
5.6 Sinovac Biotech Ltd.
5.6.1 Profile
5.6.2 Development
5.7 Changchun Changsheng Life Sciences Limited
5.8 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd
5.9 Shenzhen Kangtai Biological Products Co. Ltd
5.10 Dalian Hissen Bio-Pharm Co., Ltd
5.11 Neptunus
5.11.1 Operation
5.11.2 Vaccine Business & Development
5.12 Star Lake Bioscience
5.12.1 Operation
5.12.2 Vaccine Business & Development

Classification of Vaccines
Vaccine Industry Chain
EPI Vaccines Varieties in China, 2010
Global Human Vaccine Market Scale, 2007-2010 
Vaccine Sales Value of Global Top 5 Vaccine Manufacturers, 2007-2010
Global R&D of New Vaccines, 2009-2010
Key Mergers and Acquisitions in Vaccine Industry Worldwide, 2005-Apr.2011
Policies Concerning Vaccine Industry   
Sales Value and Growth Rate of Biological & Biochemical Product Industry in China, 2008-Nov.2010 
China’s Human Vaccine Market Scale, 2007-2010
Major Varieties and Producers of Human Vaccine in China
Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2010
Lot Release Quantity and Proportion of EPI and Extra EPI Vaccines of China, 2007-2010
Market Share Change of Extra EPI Human Vaccine in China, 2007-2010
R&D of New Human Vaccines of China, as of Apr.2011
Lot Release Quantity of Hepatitis B Vaccine in China by Dosage Form, 2007-2010
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Quantity in China, 2007-2010
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Quantity in China, 2007-2010
Market Prices of Hepatitis B Vaccine in Some Regions of China, 2010 
Meningitis Morbidity and Mortality in China, 2008-2010
Meningococcal Vaccines Lot Release Quantity in China by Type, 2007-2010
Suppliers and Lot Release Quantity of A-Group Meningococcal Vaccines, 2007-2010
Suppliers and Lot Release Quantity of A/C-Group Meningococcal Vaccines, 2007-2010
Suppliers and Lot Release Quantity of ACYW135 Meningococcal Vaccines in China, 2008-2010
Market Prices of Meningococcal Vaccines in Some Regions of China, 2010
Sales Volume Forecast of Meningococcal Vaccines by Type, 2011-2013
Sales Value Forecast of Meningococcal Vaccines by Type in China, 2011-2013
Hepatitis A Morbidity and Mortality in China, 2008-2010 
Hepatitis A Vaccine Lot Release Quantity in China, 2007-2010 
Hepatitis A Vaccine Suppliers and Lot Release Quantity in China, 2007-2010
Market Price of Hepatitis A Vaccine in China, 2010
Sales Volume Forecast of Hepatitis A Vaccine in China, 2011-2013  
Sales Revenue Forecast of Hepatitis A Vaccine in China, 2011-2013  
Influenza Morbidity and Mortality in China, 2008-2010 
H1N1 Influenza Morbidity and Mortality in China, 2009-2010 
Lot Release Quantity of Influenza Vaccine in China,2007-2010
Suppliers and Lot Release Quantity of Influenza Split Vaccine in China, 2007-2010
Influenza Subunit Vaccine Suppliers and Lot Release Quantity in China, 2007-2010
Influenza A H1N1 Influenza Vaccine Suppliers and Lot Release Quantity in China, 2009-2010
Hib Vaccine Lot Release Quantity in China, 2007-2010
Hib Vaccine Suppliers and Lot Release Quantity in China, 2007-2010
Market Prices of Hib Vaccine in Some Regions of China, 2010
Sales Volume and Growth Rate of Hib Vaccine in China, 2011-2013E  
Sales and Growth Rate of Hib Vaccine in China, 2011-2013E  
Rabies Morbidity and Mortality in China, 2007-2010
Human Rabies Vaccine Lot Release Quantity in China, 2007-2010   
Human Rabies Vaccine Lot Release Quantity in China by Type, 2007-2010 
Human Vero Cell Rabies Vaccine Suppliers and Lot Release Quantity in China, 2007-2010 
Human BHK Cell Rabies Vaccine Suppliers and Lot Release Quantity in China, 2007-2010
Market Price of Human Rabies Vaccine in Some Regions of China, 2010
Sales Volume Forecast of Human Rabies Vaccine in China, 2011-2013  
Sales Value Forecast of Human Rabies Vaccine in China, 2011-2013  
Varicella Vaccine Lot Release Quantity in China, 2007-2010  
Suppliers and Lot Release Quantity of Varicella Vaccine in China, 2007-2010
Market Price of Varicella Vaccine in Some Regions of China, 2010
Pneumococcal Vaccines Lot Release Quantity in China, 2007-2010
Suppliers of 7-Valence and 23-valence Pneumococcal Vaccines and Their Lot Release Quantities in China, 2007-2010
Market Prices of Pneumococcal Vaccines in Some Regions of China, 2010
China’s Human Vaccine Import Volume & Value, 2009-Mar. 2011  
China’s Human Vaccine Import Value by Month, 2009-Mar. 2011 
China’s Human Vaccine Export Volume by Month, 2009-Mar. 2011  
China’s Human Vaccine Export Value by Month, 2009-Mar. 2011
China Accumulated Import Volume & Value of Human Vaccine by Country, Jan.2010-Mar.2011
China’s Human Vaccine Export Volume by Month, 2009-Mar.2011 
China’s Human Vaccine Export Value by Month, 2009-Mar.2011
China’s Human Vaccine Export Volume & Value and Proportion by Country, 2010-Mar. 2011
Operating Income and Total Profit of Beijing Tiantan Biological Products Co., Ltd, 2006-2010 
Vaccine Operating Income and Growth Rate of Beijing Tiantan Biological Products Co., Ltd, 2007-2010 
Lot Release Quantity of Beijing Tiantan Biological by Product and Proportion, 2008-2010
Operating Income and Total Profit of Hualan Biological, 2007-2011
Lot Release Quantity and Proportion of Main Vaccine Products of Hualan Biological, 2010
Vaccine Revenue and Operating Margin of Hualan Biological, 2008-2010
Operating Income and Total Profit of Liaoning Chengda, 2007-2010
Vaccine Category and R&D Process of Liaoning Chengda
Biological Vaccine Revenue and Operating Margin of Liaoning, 2007-2010 
Lot Release Quantities of Major Vaccines of Liaoning Chengda, 2009-2010
Revenue and Profit of Zhifei Biological, 2007-2011
Operating Income & Gross Margin of Zhifei Biological by Product, 2010
Scheduling of the Researching Projects of Zhifei Biological, 2010-2012
Vaccines on the Market and Capacity of Yunnan Walvax
Revenue and Profit of Yunnan Walvax, 2007-2011 
Vaccine Projects of Yunnan Walvax
Vaccine Development History of Sinovac Biotech Co., Ltd, 2001-2010
Revenue and Profit of Sinovac Biotech Co., Ltd, 2008-2010
Lot Release Quantities of Sinovac Biotech Co., Ltd by Product and Proportion, 2008-2010
Lot Release Quantities of Changchun Changsheng by Product and Proportion, 2008-2010
Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical
Lot Release Quantities of Zhejiang Tianyuan Bio-Pharmaceutical by Product and Proportion, 2008-2010
Lot Release Quantity and Market Share of Hepatitis B Vaccine of Kangtai Biological, 2008-2010
Lot Release Quantities of Hissen Bio-pharm by Product and Proportion, 2008-2010
Vaccine Projects of Hissen Bio-pharm
Neptunus Operating Income & Total Profit, 2006-2011  
Star Lake Bioscience Operating Income & Total Profit, 2007-2011

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号